Eligibility Pre-hypertension NCT01568983

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
pre-hypertension or hypertension systolic blood pressure in the 130-179 mmhg range and/or diastolic blood pressure in the 85-109 mmhg range)
Beschreibung

ID.1

Datentyp

boolean

bmi 20-35 kg/m2
Beschreibung

ID.2

Datentyp

boolean

stable weight (change <4 kg previous 12 weeks)
Beschreibung

ID.3

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
regular use of blood pressure lowering agens
Beschreibung

ID.4

Datentyp

boolean

diabetes type i or ii
Beschreibung

ID.5

Datentyp

boolean

smokers
Beschreibung

ID.6

Datentyp

boolean

allergy to grape, cherries, blueberries/bilberries, black currant, aronia
Beschreibung

ID.7

Datentyp

boolean

supplements for weight loss
Beschreibung

ID.8

Datentyp

boolean

changes in pharmacological treatment of hyperlipidemia or hyperglycemia (initiation, termination or changes in dosage) last 30 days prior to inclusion or during the study period (run-in and intervention)
Beschreibung

ID.9

Datentyp

boolean

participation in a drug trial during the previous 30 days
Beschreibung

ID.10

Datentyp

boolean

Ähnliche Modelle

Eligibility Pre-hypertension NCT01568983

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
pre-hypertension or hypertension systolic blood pressure in the 130-179 mmhg range and/or diastolic blood pressure in the 85-109 mmhg range)
boolean
ID.2
Item
bmi 20-35 kg/m2
boolean
ID.3
Item
stable weight (change <4 kg previous 12 weeks)
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
regular use of blood pressure lowering agens
boolean
ID.5
Item
diabetes type i or ii
boolean
ID.6
Item
smokers
boolean
ID.7
Item
allergy to grape, cherries, blueberries/bilberries, black currant, aronia
boolean
ID.8
Item
supplements for weight loss
boolean
ID.9
Item
changes in pharmacological treatment of hyperlipidemia or hyperglycemia (initiation, termination or changes in dosage) last 30 days prior to inclusion or during the study period (run-in and intervention)
boolean
ID.10
Item
participation in a drug trial during the previous 30 days
boolean